Automated Microfluidic System for Point-of-Care Detection of Pathogens

Source: University of Toronto. AI-generated summary by biochip.com, published May 12, 2026. Not independently reviewed.

The University of Toronto has developed an automated microfluidic device that turns a saliva sample into a pathogen test result read by an ordinary glucose meter. The platform combines sample preparation, RNA extraction, molecular amplification, and signal detection in one unit, reducing the number of manual laboratory steps. It was tested with saliva samples from patients with SARS-CoV-2, the virus that causes COVID-19, and demonstrated sensitivity and specificity comparable to quantitative reverse transcription polymerase chain reaction, or qRT-PCR. qRT-PCR is a widely used laboratory method for detecting genetic material, but it typically depends on specialized instruments and trained staff. The new system instead uses small channels and chambers to move and process liquids automatically, then produces glucose as its final measurable output. A standard glucose meter, familiar from diabetes monitoring, reads that output. The approach is intended for point-of-care testing, meaning testing performed where a person receives care rather than in a distant central laboratory. If developed further, the platform could support pathogen testing in settings such as clinics, pharmacies, border crossings, and remote or low-resource locations.

A sample-to-answer device

The device is designed as a sample-to-answer platform, a term that means the user provides a biological sample and receives a result without having to carry out multiple separate laboratory procedures. In this case, a collected saliva sample enters the device and is first metered, or measured to ensure that a standardized volume moves into the assay.

That measured sample is mixed with a lysis buffer. Lysis is the process of breaking open cells or viral particles so their genetic material becomes accessible. The platform then extracts RNA, the genetic material used by many viruses, including SARS-CoV-2.

How the microfluidics handle the workflow

Microfluidics works a bit like plumbing shrunk down to the scale of droplets. Instead of a technician transferring liquid between tubes with a pipette, narrow built-in channels direct small volumes through successive processing steps. The University of Toronto system uses this approach to transfer, meter, and mix assay components with minimal manual intervention.

All of the key handling steps occur on board the device: sample metering, mixing, heating, and fluid transfer. That integration matters because manual sample preparation can be one of the hardest parts of bringing molecular tests out of conventional laboratories. A device that controls those steps may make test operation more consistent while reducing the technical training required.

Amplifying a pathogen's genetic signal

After RNA extraction, the device uses reverse transcription loop-mediated isothermal amplification, known as RT-LAMP. This method first converts RNA into DNA, then makes many copies of a target sequence. Amplification is necessary because a saliva sample may contain too little viral genetic material to detect directly.

RT-LAMP differs from conventional PCR because it can operate at a constant temperature rather than cycling repeatedly through different temperatures. The platform uses a simple onboard heater for this step. That feature can reduce reliance on the larger thermal-cycling instruments used in many qRT-PCR workflows.

Turning RNA into glucose

The platform's detection strategy is unusual: rather than producing a fluorescent signal that requires an optical reader, it converts recognition of a pathogen sequence into glucose. Think of it as a molecular lock that triggers a familiar household-style measurement. If the target genetic sequence is present after amplification, the reaction produces a glucose signal that a conventional glucose meter can measure.

This step relies on a cell-free system, meaning a biochemical reaction that uses the machinery needed to express proteins without using living cells. It also uses a toehold switch, a synthetic RNA control element that stays inactive until it encounters a matching nucleic-acid target. When the target is recognized, the switch enables production of a glucogenic reporter signal.

Using a glucose meter as the output device is central to the platform's accessibility. These meters are widely available and avoid the need for specialized signal-reading hardware. The design therefore pairs molecular detection with a readout format that could be easier to deploy outside well-equipped laboratories.

Manufacturing and potential uses

The device chip has a single-layer structure and is designed for production through standard injection molding. Injection molding is a high-volume manufacturing method in which material is shaped inside a mold, making it relevant to disposable diagnostic components. The system also incorporates onboard heating and is described as having low energy consumption.

The University of Toronto identifies several potential applications beyond SARS-CoV-2 testing. These include community-based disease detection, point-of-care testing, monitoring in places without advanced laboratory infrastructure, and testing environmental samples for pathogens or contaminants. The platform may also support multiplexing, the ability to test for more than one target in a single assay.

Why This Matters

Rapid infectious-disease testing is valuable only when people can access it quickly enough to act on the result. Centralized molecular testing can deliver highly reliable answers, but sending samples to a laboratory can add delays and requires instruments, trained personnel, and established transport systems. Those constraints become especially visible during pandemics and when emerging threats require broader surveillance.

This microfluidic platform addresses a practical bottleneck: the gap between a sophisticated molecular assay and a tool that can be used near the patient. Its main contribution is not simply detecting RNA, but integrating extraction, amplification, and reporting into a device whose final output can be read with a standard glucose meter. The platform's testing with SARS-CoV-2 patient saliva samples provides an early demonstration that this integrated approach can perform comparably to qRT-PCR.

What comes next

A provisional patent application was filed in March 2025, and the technology is positioned for continued development as a molecular diagnostic platform. Future work could determine how well the system performs across additional pathogens, environmental samples, and multiplexed test formats. Its usefulness will ultimately depend on whether the automated workflow, glucose-based output, and manufacturable chip design can retain strong performance in the varied real-world settings where rapid testing is most needed.

Topics: Microfluidics · Diabetes & metabolism · Diagnostics & precision medicine · Infectious diseases

Start here: Microfluidics explained